Back to User profile » Dr Steven Feldman
Papers published by Dr Steven Feldman:
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Therapeutic Potential of Tralokinumab in the Treatment of Atopic Dermatitis: A Review on the Emerging Clinical Data
Kelly KA, Perche PO, Feldman SR
Clinical, Cosmetic and Investigational Dermatology 2022, 15:1037-1043
Published Date: 3 June 2022
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
Light JG, Su JJ, Feldman SR
Clinical, Cosmetic and Investigational Dermatology 2021, 14:55-63
Published Date: 15 January 2021
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis
Singh R, Heron CE, Ghamrawi RI, Strowd LC, Feldman SR
ImmunoTargets and Therapy 2020, 9:255-272
Published Date: 10 November 2020
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Accountability in patient adherence
Oussedik E, Cline A, Su JJ, Masicampo EJ, Kammrath LK, Ip E, Feldman SR
Patient Preference and Adherence 2019, 13:1511-1517
Published Date: 4 September 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Treatment-resistant prurigo nodularis
Kolli SS, Haidari W, Feldman SR
Clinical, Cosmetic and Investigational Dermatology 2019, 12:345-346
Published Date: 9 May 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Satisfied patients and pediatricians: a cross-sectional analysis
Patel I, Chapman T, Camacho F, Shrestha S, Chang J, Balkrishnan R, Feldman SR
Patient Related Outcome Measures 2018, 9:299-307
Published Date: 28 August 2018
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Targeting p19 as a treatment option for psoriasis: an evidence-based review of guselkumab
Wechter T, Cline A, Feldman SR
Therapeutics and Clinical Risk Management 2018, 14:1489-1497
Published Date: 22 August 2018
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review
Murage JM, Tongbram V, Feldman SR, Malatestinic WN, Larmore CJ, Muram TM, Burge RT, Bay C, Johnson N, Clifford S, Araujo AB
Patient Preference and Adherence 2018, 12:1483-1503
Published Date: 21 August 2018
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Current treatment options for acanthosis nigricans
Patel NU, Roach C, Alinia H, Huang WW, Feldman SR
Clinical, Cosmetic and Investigational Dermatology 2018, 11:407-413
Published Date: 7 August 2018
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Barriers to treatment: describing them from a different perspective
Devine F, Edwards T, Feldman SR
Patient Preference and Adherence 2018, 12:129-133
Published Date: 17 January 2018
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Calcipotriene/betamethasone dipropionate for the treatment of psoriasis vulgaris: an evidence-based review
Patel NU, Felix K, Reimer D, Feldman SR
Clinical, Cosmetic and Investigational Dermatology 2017, 10:385-391
Published Date: 29 September 2017
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Accountability: a missing construct in models of adherence behavior and in clinical practice
![](cr_data/cache/submission_images/s135000/135895/29_may_2017_figure_3_revised_200_200_90.jpg)
Oussedik E, Foy CG, Masicampo EJ, Kammrath LK, Anderson RE, Feldman SR
Patient Preference and Adherence 2017, 11:1285-1294
Published Date: 25 July 2017
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability
Anderson MS, Nadkarni A, Cardwell LA, Alinia H, Feldman SR
Patient Preference and Adherence 2017, 11:1143-1150
Published Date: 6 July 2017
![Video](assets/img/article_icons/video.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Ethical considerations in adherence research
![](assets/img/youtube_social_icon_dark.png)
![](http://img.youtube.com/vi/iZ6smh81CNY/1.jpg)
Patel NU, Moore BA, Craver RF, Feldman SR
Patient Preference and Adherence 2016, 10:2429-2435
Published Date: 5 December 2016
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Interventions to increase adherence to acne treatment
Moradi Tuchayi S, Alexander TM, Nadkarni A, Feldman SR
Patient Preference and Adherence 2016, 10:2091-2096
Published Date: 11 October 2016
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
New developments in the treatment of rosacea – role of once-daily ivermectin cream
Cardwell LA, Alinia H, Moradi Tuchayi S, Feldman SR
Clinical, Cosmetic and Investigational Dermatology 2016, 9:71-77
Published Date: 18 March 2016
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Internet-based adherence interventions for treatment of chronic disorders in adolescents
Bass AM, Farhangian ME, Feldman SR
Adolescent Health, Medicine and Therapeutics 2015, 6:91-99
Published Date: 26 May 2015
![Noteworthy comment: IL-17 therypy is the second generation of biological therapies in psoriasis. The review provides an up-to-date review on knowledge of one of the new anti-IL-17 compounds.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Clinical potential of brodalumab in the management of psoriasis: the evidence to date
Sandoval LF, Williams B, Feldman SR
Psoriasis: Targets and Therapy 2015, 5:35-41
Published Date: 11 March 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Emerging treatment options for psoriasis
Taheri A, Sandoval LF, Moradi Tuchayi S, Alinia H, Mansoori P, Feldman SR
Psoriasis: Targets and Therapy 2014, 4:27-35
Published Date: 18 August 2014
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Self-management in patients with psoriasis
Pathak SN, Scott PL, West C, Feldman SR
Psoriasis: Targets and Therapy 2014, 4:19-26
Published Date: 10 July 2014
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Once-daily topical treatment for psoriasis: calcipotriene + betamethasone two-compound topical formulation
Shepherd J, Taheri A, Feldman SR
Clinical, Cosmetic and Investigational Dermatology 2014, 7:19-22
Published Date: 19 December 2013
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The effect of reminder systems on patients' adherence to treatment
Fenerty SD, West C, Davis SA, Kaplan SG, Feldman SR
Patient Preference and Adherence 2012, 6:127-135
Published Date: 10 February 2012